Nuvation Bio to Participate in the Jefferies Virtual Healthcare Conference

Nuvation Bio (NYSE: NUVB) announced that Dr. David Hung, CEO, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 9:00 a.m. ET.

Rhea-AI Summary

Nuvation Bio (NYSE: NUVB) announced that Dr. David Hung, CEO, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 9:00 a.m. ET. The event will be available for live viewing on the company's website under 'Events & Presentations' and archived for 30 days post-event. Nuvation Bio focuses on developing innovative oncology therapies, with a portfolio of six distinct product candidates aimed at challenging cancer types. Founded in 2018, Nuvation Bio is headquartered in New York and San Francisco.

Argus Session date unavailable

+0.28% session move Open Argus

Details

News Market Reaction – NUVB

The recorded move for NUVB in the trading session of this news was +0.28%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, May 26, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that David Hung, M.D., founder and chief executive officer of Nuvation Bio, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021, at 9:00 a.m. ET.

The fireside chat will be webcast live and can be accessed under "Events & Presentations" in the "Investors" section of the Company's website at www.nuvationbio.com. The webcast will be archived for a period of 30 days following the conclusion of the live event.

About Nuvation Bio

Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco. For more information, please visit www.nuvationbio.com.

Nuvation Bio Investor Contact:
ir@nuvationbio.com

Nuvation Bio Media Contact:
Argot Partners
Leo Vartorella
leo@argotpartners.com  

View original content to download multimedia:http://www.prnewswire.com/news-releases/nuvation-bio-to-participate-in-the-jefferies-virtual-healthcare-conference-301299313.html

SOURCE Nuvation Bio, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Nuvation Bio's participation in the Jefferies Virtual Healthcare Conference?

Nuvation Bio, under the leadership of CEO Dr. David Hung, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 9:00 a.m. ET.

How can I watch Nuvation Bio's presentation at the conference?

The fireside chat will be webcast live on Nuvation Bio's website in the 'Events & Presentations' section and will be archived for 30 days after the event.

What is Nuvation Bio's focus in the biopharmaceutical sector?

Nuvation Bio is dedicated to tackling unmet needs in oncology through the development of novel therapeutic candidates, with six distinct oncology product candidates in its portfolio.

When was Nuvation Bio founded?

Nuvation Bio was founded in 2018 by Dr. David Hung, a biopharma industry veteran.

Where are Nuvation Bio's offices located?

Nuvation Bio has offices in New York and San Francisco.